· Laquinimod - results of Phase III BRAVO trial reinforce unique profile of laquinimod for multiple sclerosis treatment · TASQ - recruitment of patients for the Phase III trial ongoing · TASQ - partnership agreement initiated with Ipsen · ANYARA - Phase III trial continues according to plan · 57-57 - preparation for the start of the SSC exploratory clinical trial in progress · ISI - project is proceeding as planned · RhuDex(TM) - preparations for continued clinical development in progress · Net sales SEK 228.8 M (6.1) · Operating profit SEK 70.6 M (loss: 102,4) · Profit after tax SEK 77.7 M (loss: 108.3) · Earnings per share for the period amounted to SEK 1.14 (loss: 1.67) For further information, please contact: Tomas Leanderson President and CEO Tel: +46 (0)46-19 20 95 Hans Kolam CFO Tel: +46 (0)46-19 20 44 Active Biotech AB (Corp. Reg. No: 556223-9227) PO Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00 This report is also available at www.activebiotech.com Active Biotech AB Interim Report January – June 2011: http://hugin.info/1002/R/1537777/469595pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Active Biotech via Thomson Reuters ONE [HUG#1537777]
